To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
72
Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
Cisplatin 30mg,intrapleural administration,each 2 week
PLA 304 hospital
Beijing, Beijing Municipality, China
Number of Participants With "Complete Response" and "Partial Response"
Response assessed by type-B ultrasonic tests; Complete remission (CR) was considered when the accumulated fluid had disappeared and was stable for at least four weeks; partial remission (PR) was considered when \>50% of the accumulated fluid had disappeared, symptoms had improved, and the remaining fluid had failed to increase for at least four weeks; The total efficiency ORR was calculated by taking the sum of CR+PR
Time frame: from randomization, This treatment was given every two weeks,responses were made by biweekly
Median Progression Free Survival (PFS)
Time frame: baseline to biweekly,until disease progression
Overall Survival (OS)
Time frame: randomization to four weeks,until death
Adverse Reactions
Time frame: Up to 1 month after the last treatment
Qualify of Life (QoL)
Time frame: baseline to biweekly,until death
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.